IBC2019: Innovation Awards Shortlist Announced
From 6K to holographic projection and from esports to the FIFA World Cup, this year’s 10 IBC Innovation Awards finalists show a clear trend towards global co-operation and remarkable advances in bringing new engagement to content.
Representing the very best of technical excellence in pursuit of real benefits for producers and viewers alike, the Innovation Awards judges were “astounded by the range of imaginative projects submitted and had some really tough decisions to make,” said Michael Lumley, Chair of the international judging panel.
“Although we never look for a theme in our list of finalists, the shortlist usually reflects the wider industry,” Lumley added. “This year you can definitely see that there are a number of projects which are global in their scale and which use new opportunities in connectivity to bring us astounding images, whether that is capturing life under the sea or the excitement of sports.”
The calibre of this year’s shortlist demonstrates that the IBC Innovation Awards are the leading recognition for the application of cutting-edge technology in media and entertainment. The Innovation Awards are unique in that they do not go to new products, but instead to innovative uses of technology, bringing new creative, operational or commercial opportunities to users.
There are three categories: the first, Content Creation, recognises excellence in creating content. The four finalists for this category are:
- Fox Sports for its augmented reality studio for Nascar
- Riot Games for its remote production in Los Angeles of the League of Legends World Championships in Seoul
- SailGP and Timeline Television, again for remote production, this time of SailGP, a new annual, global sports championship re-defining the sport of sailing
- Vodafone in Romania for enabling an 11-year-old guitarist to join a rock band on stage, through a 5G remote link and holographic projection
For the Content Distribution category, the finalists are:
- Associated Press, for its technical audacity in using lasers through open water to bring broadcast quality video from depths of 200m off the Seychelles
- BT Sport for its practical demonstration of the use of 5G for remote production
- COPA90 for its radical new approach to social media and fan engagement globally, from the FIFA World Cup in 2018
The shortlist for the Content Everywhere category is:
- Deutsche Telekom for advancing immersive video experiences with a 6k resolution 360˚ service
- ETV Bharat in India for building a news production and playout platform at a remarkable scale for 24 OTT channels in 13 languages, served by 5,000 journalists
- Mediapro for delivering matches and fan entertainment from LaLiga Spanish football, on Facebook Watch in Indian Subcontinent
Anil Wanvari, Founder, CEO and editor-in-chief of indiantelevision.com, joined the judging panel in London this year, travelling from Mumbai. He commented: “The chance to sit with a group from America, the Middle East and Europe to discuss, debate and explore this extensive list of entries was very exciting.”
“What struck me most, as a first-time judge, is that the entries come from all around the world, each bringing its own unique take on how to engage with audiences today,” he continued. “Agreeing a shortlist of just 10 was really difficult. There were some ground-breaking projects which have achieved great things but did not quite make it in a remarkable year for this competition.”
While the shortlist is announced today, the identity of the winners remains a closely guarded secret until the IBC2019 Awards Ceremony, held at 18:30 on Sunday 15 September. This year IBC is introducing two new awards: the Young Pioneer Award, recognising rising talent in our industry, and the Social Impact Award, recognising those making a positive impact in the wider world. The winners of all these awards and IBC’s highest accolade, the International Honour for Excellence, will be announced at the IBC Awards Ceremony.
Entry to the IBC Awards Ceremony is included in your free IBC exhibition visitor pass. Register now: show.ibc.org/register.
## ENDS ##
Notes to Editors:
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
Conference: 13 - 17 September 2019
Exhibition: 13 - 17 September 2019
For more information about IBC2019 visit: show.ibc.org
For further information, please contact:
Amy Swallow, Bubble Agency
T: +44 7872 831167
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu